Search Results - "Nooij, M"

Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials by Whelan, J.S., Jinks, R.C., McTiernan, A., Sydes, M.R., Hook, J.M., Trani, L., Uscinska, B., Bramwell, V., Lewis, I.J., Nooij, M.A., van Glabbeke, M., Grimer, R.J., Hogendoorn, P.C.W., Taminiau, A.H.M., Gelderblom, H.

“…Neoadjuvant chemotherapy improves outcome in osteosarcoma. Determination of optimum regimens for survival, toxicity and prognostic factors requires randomised…”
Get full text

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer by Paridaens, R., Dirix, L., Lohrisch, C., Beex, L., Nooij, M., Cameron, D., Biganzoli, L., Cufer, T., Duchateau, L., Hamilton, A., Lobelle, J. P., Piccart, M.

“…Background: Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored…”
Get full text

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer by Rodenhuis, S., Bontenbal, M., van Hoesel, Q.G.C.M., Smit, W.M., Nooij, M.A., Voest, E.E., van der Wall, E., Hupperets, P., van Tinteren, H., Peterse, J.L., van de Vijver, M.J., de Vries, E.G.E.

“…Background: High-dose chemotherapy in the adjuvant treatment of breast cancer has been abandoned by many. Patients and methods: 885 patients with stage III…”
Get full text

Molecular subtypes of breast cancer and amplification of topoisomerase IIα : predictive role in dose intensive adjuvant chemotherapy by HANNEMANN, J, KRISTEL, P, DE VRIES, E. G. E, RODENHUIS, S, VAN DE VIJVER, M. J, VAN TINTEREN, H, BONTENBAL, M, VAN HOESEL, Q. G. C. M, SMIT, W. M, NOOIJ, M. A, VOEST, E. E, VAN DER WALL, E, HUPPERETS, P

“…Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour. In a retrospective analysis, we determined…”
Get full text

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group by Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., Vermorken, J. B.

“…Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate…”
Get full text

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’ by Atalay, G., Dirix, L., Biganzoli, L., Beex, L., Nooij, M., Cameron, D., Lohrisch, C., Cufer, T., Lobelle, J. P., Mattiaci, M. R., Piccart, M., Paridaens, R.

“…Background: The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly…”
Get full text

Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: A population-based study by Jansen-Landheer, M.L.E.A, Krijnen, P, Oostindiër, M.J, Kloosterman-Boele, W.M, Noordijk, E.M, Nooij, M.A, Steup, W.H, Taminiau, A.H.M, Vree, R, Hogendoorn, P.C.W, Tollenaar, R.A.E.M, Gelderblom, H

“…Abstract Aim The majority of clinicians, radiologists and pathologists have limited experience with soft tissue sarcomas. In 2004, national guidelines were…”
Get full text

Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists’ preferences by Nooij, M.A, de Haes, J.C.J.M, Beex, L.V.A.M, Wildiers, J, Klijn, J, Becquart, D, Jassem, J, Engelsman, E, Duchateau, L

“…The optimal duration of cytostatic treatment for metastatic breast cancer is still a matter of debate. Possible gain in the duration of remission has to be…”
Get full text

Response Shift in Quality of Life Measurement in Early-Stage Breast Cancer Patients Undergoing Radiotherapy by Jansen, S J, Stiggelbout, A M, Nooij, M A, Noordijk, E M, Kievit, J

“…In medicine, response shift refers to a change - as a result of an event such as a therapy - in the meaning of one's self-evaluation of quality of life. Due to…”
Get full text

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer by Piccart, M J, Klijn, J, Paridaens, R, Nooij, M, Mauriac, L, Coleman, R, Bontenbal, M, Awada, A, Selleslags, J, Van Vreckem, A, Van Glabbeke, M

“…To confirm the efficacy of docetaxel in patients with breast cancer previously treated with one chemotherapy regimen for advanced or metastatic disease and to…”
Get more information

Patients' preferences for adjuvant chemotherapy in early-stage breast cancer : is treatment worthwhile? by JANSEN, S. J. T, KIEVIT, J, NOOIJ, M. A, DE HAES, J. C. J. M, OVERPELT, I. M. E, VAN SLOOTEN, H, MAARTENSE, E, STIGGELBOUT, A. M

“…When making decisions about adjuvant chemotherapy for early-stage breast cancer, costs and benefits of treatment should be carefully weighed. In this process,…”
Get full text

Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study by Nooij, M.A., Whelan, J., Bramwell, V.H.C., Taminiau, A.T., Cannon, S., Hogendoorn, P.C.W., Pringle, J., Uscinska, B.M., Weeden, S., Kirkpatrick, A., Glabbeke, M.v., Craft, A.W.

“…There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant…”
Get full text

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients by Nieboer, P, de Vries, E G E, Mulder, N H, Rodenhuis, S, Bontenbal, M, van der Wall, E, van Hoesel, Q G, Smit, W M, Hupperets, P, Voest, E E, Nooij, M A, Boezen, H M, van der Graaf, W T A

“…Neutropenia following high-dose chemotherapy leads to a high incidence of infectious complications, of which central venous catheter-related infections…”
Get full text

Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas by Anninga, J.K, van de Vijver, M.J, Cleton-Jansen, A.M, Kristel, P.M.P, Taminiau, A.H.M, Nooij, M, Egeler, R.M, Hogendoorn, P.C.W

“…The aim of our study was to determine whether or not the tyrosine kinase receptor, HER2 (also known as ErbB2/Her2/ neu), is overexpressed in human…”
Get full text

Survival of patients with ovarian cancer due to a mismatch repair defect by Crijnen, Th E M, Janssen-Heijnen, M L G, Gelderblom, H, Morreau, J, Nooij, M A, Kenter, G G, Vasen, H F A

“…Hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) is characterized by the development of cancer of the colorectum, endometrium and other…”
Get full text

Bleomycin, Methotrexate, and CCNU in Locally Advanced or Recurrent, Inoperable, Squamous-Cell Carcinoma of the Vulva: An EORTC Gynaecological Cancer Cooperative Group Study by Wagenaar, H.C., Colombo, N., Vergote, I., Hoctin-Boes, G., Zanetta, G., Pecorelli, S., Lacave, A.J., van Hoesel, Q., Cervantes, A., Bolis, G., Namer, M., Lhommé, C., Guastalla, J.P., Nooij, M.A., Poveda, A., Scotto di Palumbo, V., Vermorken, J.B.

“…Objectives. To investigate tumor response rate and treatment toxicity of a modified combination chemotherapy consisting of bleomycin (B), methotrexate (M), and…”
Get full text

Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863) by Beex, L., Rose, C., Mouridsen, H., Jassem, J., Nooij, M., Estape, J., Paridaens, R., Piccart, M., Gorlia, T., Lardenoije, S., Baila, L.

“…Continuous ligand depletion of endocrine responsive tumours may enhance resistance to therapy. Intermittent treatment with tamoxifen (T) was considered to…”
Get full text

Diabetes insipidus and adrenal insufficiency in a patient with metastatic breast cancer by NETELENBOS, T, NOOIJ, M. A, NORTIER, J. W. R

“…A patient previously treated for bilateral breast cancer with mastectomy, radiation therapy and in remission on hormonal therapy for more than five years…”
Get full text

APROSYS: Advances in secondary safety research by van Schijndel-de Nooij, M., Wismans, J.

“…Secondary, or passive, safety includes the most important strategies to reduce the traffic trauma problem. This field concerns the protection of road users…”
Get full text

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group by van Wijk, F.H, Lhommé, C, Bolis, G, Scotto di Palumbo, V, Tumolo, S, Nooij, M, de Oliveira, C.F, Vermorken, J.B

“…The aim of this study was to investigate the efficacy and toxicity of carboplatin given as monotherapy in endometrial adenocarcinoma. Cisplatin is one of the…”
Get full text